ID
45367
Description
Principal Investigator: Winnie S. Liang, PhD, Translational Genomics Research Institute, Phoenix, AZ, USA MeSH: Pancreatic Neoplasms,Carcinoma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000550 In this study, we whole genome sequenced tumor/normal pairs from three pancreatic adenocarcinoma patients to separately characterize each patient with respect to somatic alterations. For 2 patients for whom tumor RNA was available, we also performed RNA sequencing to evaluate gene expression changes. While additional sequencing is needed to improve our understanding of the disease, the information acquired from this study contributes to our knowledge base on pancreatic cancer and helps to establish a foundation for identifying and developing more efficacious treatments for patients.
Link
Keywords
Versions (1)
- 11/4/22 11/4/22 - Chiara Middel
Copyright Holder
Winnie S. Liang, PhD, Translational Genomics Research Institute, Phoenix, AZ, USA
Uploaded on
November 4, 2022
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
dbGaP phs000550 Characterization of Pancreatic Adenocarcinoma Patients Using NGS
Subject ID, sample ID, and sample use variable obtained from participants with pancreatic adenocarcinoma and involved in the "Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, type of research were used, and consent group of participants with pancreatic adenocarcinoma and involved in the "Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing" project.
- Subject ID, sample ID, and sample use variable obtained from participants with pancreatic adenocarcinoma and involved in the "Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing" project.
- Subject ID, age, sex, race, and current status of participants with pancreatic adenocarcinoma and involved in the "Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing" project.
- Sample ID, body site where sample was collected, analyte type of samples, tumor status, primary tumor, metastasis, or transformed cell line, primary tumor location, tumor stage of samples, and type of tumor treatment for samples obtained from participants with pancreatic adenocarcinoma and involved in the "Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing" project.
Similar models
Subject ID, sample ID, and sample use variable obtained from participants with pancreatic adenocarcinoma and involved in the "Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, type of research were used, and consent group of participants with pancreatic adenocarcinoma and involved in the "Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing" project.
- Subject ID, sample ID, and sample use variable obtained from participants with pancreatic adenocarcinoma and involved in the "Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing" project.
- Subject ID, age, sex, race, and current status of participants with pancreatic adenocarcinoma and involved in the "Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing" project.
- Sample ID, body site where sample was collected, analyte type of samples, tumor status, primary tumor, metastasis, or transformed cell line, primary tumor location, tumor stage of samples, and type of tumor treatment for samples obtained from participants with pancreatic adenocarcinoma and involved in the "Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing" project.